Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 24908 | 3.075 |
09:34 ET | 24136 | 3.12 |
09:36 ET | 2900 | 3.11 |
09:38 ET | 23439 | 3.102 |
09:39 ET | 1442 | 3.095 |
09:41 ET | 1103 | 3.095 |
09:43 ET | 4116 | 3.075 |
09:45 ET | 2757 | 3.065 |
09:48 ET | 15133 | 3.065 |
09:52 ET | 18856 | 3.06 |
09:54 ET | 3221 | 3.08 |
09:56 ET | 1535 | 3.095 |
09:57 ET | 300 | 3.095 |
09:59 ET | 1300 | 3.11 |
10:01 ET | 2448 | 3.105 |
10:03 ET | 36002 | 3.08 |
10:06 ET | 3501 | 3.075 |
10:08 ET | 11431 | 3.0698 |
10:10 ET | 65896 | 3.075 |
10:12 ET | 6284 | 3.0801 |
10:14 ET | 15077 | 3.095 |
10:15 ET | 12307 | 3.105 |
10:17 ET | 18773 | 3.095 |
10:19 ET | 34362 | 3.115 |
10:21 ET | 4081 | 3.095 |
10:24 ET | 5860 | 3.115 |
10:26 ET | 6111 | 3.125 |
10:28 ET | 6521 | 3.125 |
10:30 ET | 7403 | 3.105 |
10:33 ET | 7870 | 3.105 |
10:35 ET | 9014 | 3.095 |
10:37 ET | 4585 | 3.09 |
10:39 ET | 5322 | 3.1 |
10:42 ET | 4109 | 3.095 |
10:44 ET | 25913 | 3.12 |
10:46 ET | 8470 | 3.11 |
10:48 ET | 3335 | 3.12 |
10:50 ET | 16613 | 3.165 |
10:51 ET | 5590 | 3.155 |
10:53 ET | 2600 | 3.145 |
10:55 ET | 15174 | 3.135 |
10:57 ET | 2593 | 3.135 |
11:00 ET | 9390 | 3.125 |
11:02 ET | 7876 | 3.125 |
11:04 ET | 10976 | 3.13 |
11:06 ET | 2294 | 3.125 |
11:08 ET | 21353 | 3.125 |
11:09 ET | 4308 | 3.125 |
11:11 ET | 25191 | 3.135 |
11:13 ET | 3058 | 3.135 |
11:15 ET | 2392 | 3.135 |
11:18 ET | 26291 | 3.125 |
11:20 ET | 3442 | 3.125 |
11:22 ET | 14237 | 3.125 |
11:24 ET | 900 | 3.12 |
11:26 ET | 100 | 3.12 |
11:27 ET | 8636 | 3.11 |
11:29 ET | 3675 | 3.105 |
11:31 ET | 12744 | 3.095 |
11:33 ET | 2418 | 3.085 |
11:36 ET | 3100 | 3.085 |
11:38 ET | 10782 | 3.085 |
11:40 ET | 1100 | 3.08 |
11:42 ET | 500 | 3.085 |
11:44 ET | 200 | 3.085 |
11:45 ET | 200 | 3.08 |
11:47 ET | 3230 | 3.085 |
11:49 ET | 10148 | 3.095 |
11:51 ET | 1918 | 3.095 |
11:54 ET | 4212 | 3.09 |
11:56 ET | 8299 | 3.08 |
11:58 ET | 3165 | 3.085 |
12:00 ET | 3462 | 3.08 |
12:02 ET | 9993 | 3.095 |
12:03 ET | 2426 | 3.095 |
12:05 ET | 900 | 3.09 |
12:07 ET | 20999 | 3.085 |
12:09 ET | 10635 | 3.085 |
12:12 ET | 600 | 3.08 |
12:14 ET | 1100 | 3.08 |
12:16 ET | 8012 | 3.08 |
12:18 ET | 2165 | 3.08 |
12:20 ET | 3864 | 3.08 |
12:21 ET | 5615 | 3.09 |
12:23 ET | 2339 | 3.085 |
12:25 ET | 2073 | 3.09 |
12:27 ET | 1663 | 3.09 |
12:30 ET | 3900 | 3.0801 |
12:32 ET | 2084 | 3.08 |
12:34 ET | 35575 | 3.055 |
12:36 ET | 22462 | 3.08 |
12:38 ET | 2555 | 3.07 |
12:39 ET | 7023 | 3.07 |
12:41 ET | 10298 | 3.04 |
12:43 ET | 7900 | 3.0512 |
12:45 ET | 44849 | 3.085 |
12:48 ET | 13988 | 3.085 |
12:50 ET | 1342 | 3.085 |
12:52 ET | 33559 | 3.07 |
12:54 ET | 1412 | 3.07 |
12:56 ET | 12731 | 3.075 |
12:57 ET | 3892 | 3.07 |
12:59 ET | 2310 | 3.075 |
01:01 ET | 2300 | 3.07 |
01:03 ET | 253970 | 3.095 |
01:06 ET | 10251 | 3.08 |
01:08 ET | 1567 | 3.085 |
01:10 ET | 300 | 3.09 |
01:12 ET | 4112 | 3.08 |
01:14 ET | 1000 | 3.08 |
01:15 ET | 8160 | 3.08 |
01:17 ET | 2041 | 3.08 |
01:19 ET | 2779 | 3.07 |
01:21 ET | 26259 | 3.075 |
01:24 ET | 200 | 3.075 |
01:26 ET | 4934 | 3.08 |
01:28 ET | 26595 | 3.09 |
01:30 ET | 11317 | 3.095 |
01:32 ET | 1325 | 3.095 |
01:33 ET | 14521 | 3.09 |
01:35 ET | 46967 | 3.09 |
01:37 ET | 24607 | 3.085 |
01:39 ET | 54151 | 3.1 |
01:42 ET | 45464 | 3.1 |
01:44 ET | 10066 | 3.105 |
01:46 ET | 20783 | 3.12 |
01:48 ET | 621 | 3.125 |
01:50 ET | 6580 | 3.13 |
01:51 ET | 8587 | 3.135 |
01:53 ET | 3170 | 3.135 |
01:55 ET | 3300 | 3.135 |
01:57 ET | 3611 | 3.14 |
02:00 ET | 5334 | 3.12 |
02:02 ET | 400 | 3.12 |
02:04 ET | 13071 | 3.135 |
02:06 ET | 7669 | 3.13 |
02:08 ET | 3900 | 3.14 |
02:09 ET | 14420 | 3.14 |
02:11 ET | 14120 | 3.14 |
02:13 ET | 12387 | 3.14 |
02:15 ET | 25627 | 3.135 |
02:18 ET | 18170 | 3.145 |
02:20 ET | 900 | 3.1449 |
02:22 ET | 1696 | 3.15 |
02:24 ET | 12940 | 3.145 |
02:26 ET | 4453 | 3.15 |
02:27 ET | 868 | 3.15 |
02:29 ET | 4102 | 3.145 |
02:31 ET | 7673 | 3.14 |
02:33 ET | 14078 | 3.135 |
02:36 ET | 2303 | 3.12 |
02:38 ET | 1923 | 3.12 |
02:40 ET | 14534 | 3.11 |
02:42 ET | 3246 | 3.115 |
02:44 ET | 9979 | 3.09 |
02:45 ET | 5449 | 3.08 |
02:47 ET | 4230 | 3.08 |
02:49 ET | 2400 | 3.08 |
02:51 ET | 21695 | 3.095 |
02:54 ET | 6826 | 3.11 |
02:56 ET | 2100 | 3.1 |
02:58 ET | 1400 | 3.105 |
03:00 ET | 1700 | 3.105 |
03:02 ET | 1619 | 3.11 |
03:03 ET | 12445 | 3.1 |
03:05 ET | 6732 | 3.105 |
03:07 ET | 1600 | 3.105 |
03:09 ET | 9626 | 3.085 |
03:12 ET | 6154 | 3.085 |
03:14 ET | 1054 | 3.085 |
03:16 ET | 5559 | 3.09 |
03:18 ET | 10764 | 3.08 |
03:20 ET | 8948 | 3.07 |
03:21 ET | 4996 | 3.075 |
03:23 ET | 9151 | 3.08 |
03:25 ET | 7759 | 3.07 |
03:27 ET | 5307 | 3.07 |
03:30 ET | 29432 | 3.085 |
03:32 ET | 10306 | 3.115 |
03:34 ET | 10438 | 3.13 |
03:36 ET | 13230 | 3.115 |
03:38 ET | 14076 | 3.09 |
03:39 ET | 10384 | 3.09 |
03:41 ET | 9364 | 3.11 |
03:43 ET | 12109 | 3.095 |
03:45 ET | 2800 | 3.1 |
03:48 ET | 4860 | 3.1 |
03:50 ET | 5200 | 3.095 |
03:52 ET | 54907 | 3.11 |
03:54 ET | 8650 | 3.105 |
03:56 ET | 22519 | 3.12 |
03:57 ET | 31457 | 3.115 |
03:59 ET | 232851 | 3.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 748.9M | -9.9x | --- |
89Bio Inc | 739.8M | -3.9x | --- |
Savara Inc | 728.4M | -11.9x | --- |
Dianthus Therapeutics Inc | 740.2M | -8.8x | --- |
Perspective Therapeutics Inc | 722.3M | -6.8x | --- |
Viridian Therapeutics Inc | 786.3M | -2.7x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $748.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.